Coronavirus (COVID-19) Update
AmerisourceBergen and our global businesses are highly engaged during the ongoing spread of the novel COVID-19 “Coronavirus."

Kelly Ratliff publishes article in Specialty Pharmacy Times: "Achieve Gold Standard Oral Oncology Drug Adherence Through Collaboration"

Oncology patients are historically among the most therapy-adherent patient populations. Recently, however, nonadherence has become an emerging challenge. Significant advancements in cancer treatment now give patients the opportunity to maintain their daily lifestyle with fewer adverse effects and better long-term disease management, but these same advancements have taken away some of the direct interaction among providers and patients that occurred when care was administered in the clinic. The greater freedom and independence that are among the advantages patients gain from oral therapies has ultimately led to lower adherence rates.